BridgeBio Pharma, Inc. - Common Stock (BBIO)

76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.

A second positive "domino" fell for BridgeBio on Wednesday after the company reported promising results in a genetic disease.

BridgeBio now intends to file a new drug application for the therapy's approval in the first half of 2026.

BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study.

The company ran an exploratory analysis of its drug, Attruby, in patients with cardiomyopathy due to TTR amyloidosis.

BridgeBio Pharma (BBIO) shows strong technicals with a perfect 10 rating. Currently in a consolidation pattern, it may be poised for a breakout above resistance, offering a potential entry for investors.

BridgeBio Pharma (BBIO) shows strong breakout potential with a perfect Technical Rating of 10 and Setup Rating of 9, signaling robust momentum and consolidation. Ideal for traders eyeing high-probability biotech plays.

BridgeBio Pharma reports mixed Q2 2025 results with revenue beating estimates but EPS missing, causing an 11% stock drop. Strong prescription growth contrasts with profitability concerns.

Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility.

The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market.

Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the ATTR-CM market in the next 3 years.

BridgeBio's acoramidis wins Japan's approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca's Alexion to market it.